Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation - Concepedia

Concepedia

Publication | Closed Access

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

175

Citations

11

References

2018

Year

James Chih‐Hsin Yang, Shirish M. Gadgeel, Lecia VanDam Sequist, Chien-Liang Wu, Vassiliki A. Papadimitrakopoulou, Wu‐Chou Su, Joseph Fiore, Sanatan Saraf, Harry Raftopoulos, Amita Patnaik

Journal of Thoracic Oncology

Advanced NsclcFirst-line TherapyMedicineImmunologyPathologyImmune Checkpoint InhibitorSensitizing Egfr MutationPharmacotherapyCancer TreatmentOncologyRadiation OncologyNovel Therapy

References

	Year	Citations

Page 1

Page 1